Leishmaniasis, Cutaneous Clinical Trial
— CEFELEISHOfficial title:
Investigation of an Outbreak Situation of Cutaneous Leishmaniasis Among Military Personnel in French Guiana (CEFELEISH)
NCT number | NCT04888130 |
Other study ID # | CEFELEISH |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | December 1, 2020 |
Est. completion date | May 7, 2021 |
Verified date | May 2021 |
Source | Centre Hospitalier de Cayenne |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Clinical, epidemiological, therapeutic and microbiological investigation of an outbreak of cutaneous Leishmaniasis that occurred among military personnel in French Guiana in 2020.
Status | Completed |
Enrollment | 44 |
Est. completion date | May 7, 2021 |
Est. primary completion date | March 1, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | - Inclusion criteria * for cases : - Confirmed cutaneous leishmaniasis (compatible clinical lesion + a positive microbiological test or cure after probabilistic anti-leishmania treatment) in a military personnel who participated in the CEFE training *for controls : - Absence of a suspicious lesion of leishmaniasis in a military personnel who participated in training at CEFE NB: All concerned are adults. - Non inclusion criteria *for cases : - Confirmed cutaneous leishmaniasis not having been contracted after a training at CEFE - Unconfirmed cutaneous leishmaniasis - Opposition to the use of their data and / or the completion of the questionnaire - Refusal of participation *for controls : - Opposition to the taking of the questionnaire - Refusal of participation training - Exclusion criteria Withdrawal of participation |
Country | Name | City | State |
---|---|---|---|
French Guiana | General Hospital of Cayenne | Cayenne |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier de Cayenne | Centre Médical Inter-Armées (CMIA) de Cayenne, French Guiana, Centre Médical Inter-Armées (CMIA) de Kourou, French Guiana, Centre National de Référence des Leishmanioses, CHU de Montpellier, France, Direction Interarmées du Service de Santé des Armées (DIASS) de Cayenne, French Guiana |
French Guiana,
Loiseau R, Nabet C, Simon S, Ginouves M, Brousse P, Blanchet D, Demar M, Couppie P, Blaizot R. American cutaneous leishmaniasis in French Guiana: an epidemiological update and study of environmental risk factors. Int J Dermatol. 2019 Nov;58(11):1323-1328. doi: 10.1111/ijd.14625. Epub 2019 Sep 16. — View Citation
Martin-Blondel G, Iriart X, El Baidouri F, Simon S, Mills D, Demar M, Pistone T, Le Taillandier T, Malvy D, Gangneux JP, Couppie P, Munckhof W, Marchou B, Ravel C, Berry A. Outbreak of Leishmania braziliensis Cutaneous Leishmaniasis, Saül, French Guiana. Emerg Infect Dis. 2015 May;21(5):892-4. doi: 10.3201/eid2105.141181. — View Citation
Simon S, Nacher M, Carme B, Basurko C, Roger A, Adenis A, Ginouves M, Demar M, Couppie P. Cutaneous leishmaniasis in French Guiana: revising epidemiology with PCR-RFLP. Trop Med Health. 2017 Feb 28;45:5. doi: 10.1186/s41182-017-0045-x. eCollection 2017. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Frequency of responses collected during questionnaire | • For the case-control part: Primary endpoint: comparison of the frequency of responses collected during the questionnaire between cases and witnesses | 5 months | |
Primary | Severity of leishmaniasis | • For the cohort study part: Primary endpoint: severity of leishmaniasis (clinical presentation, cure after Pentacarinat) Associations will be sought between this main criterion and the phylogeny of the strains and the patient's intrinsic risk factors. | 5 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01140191 -
Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT03999970 -
A Clinical Study to Develop an Uninfected Sand Fly Biting Protocol
|
N/A | |
Completed |
NCT00111553 -
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis
|
Phase 1 | |
Recruiting |
NCT03762070 -
Evaluation of a Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Peru
|
||
Completed |
NCT02894008 -
A Study of a New Leishmania Vaccine Candidate ChAd63-KH
|
Phase 2 | |
Completed |
NCT03303898 -
ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE -
|
N/A | |
Recruiting |
NCT05094908 -
Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis
|
Phase 1 | |
Completed |
NCT01083576 -
Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama
|
Phase 2 | |
Completed |
NCT03445897 -
Miltefosine Plus IL Pentamidine for Bolivian CL
|
Phase 2 | |
Withdrawn |
NCT04072874 -
Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis.
|
Phase 1/Phase 2 | |
Completed |
NCT01032382 -
Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)
|
Phase 2 | |
Completed |
NCT00480883 -
Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol
|
N/A | |
Recruiting |
NCT05708625 -
Intralesional Voriconazole, or Intralesional Cryotherapy, or Oral Doxycycline in the Treatment of Cutaneous Leishmaniasis
|
Phase 3 | |
Completed |
NCT04841239 -
Development of Topical Herbal Formulations for Treatment of Cutaneous Leishmaniasis
|
N/A | |
Completed |
NCT00469495 -
Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis
|
N/A | |
Completed |
NCT03294161 -
Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT03969134 -
A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL
|
Phase 2 | |
Completed |
NCT03096457 -
Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia
|
Phase 2/Phase 3 | |
No longer available |
NCT01641796 -
Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis
|
||
No longer available |
NCT00508963 -
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis
|